title: Disease stage of chronic hepatitis C assessed by both peritoneoscopic and histologic findings and its relationship with response to interferon therapy.
abstract: BACKGROUND
  Disease stage in patients with chronic hepatitis C was assessed by both peritoneoscopy and histology and correlated with responses to interferon therapy.
  
  
  METHODS
  The subjects were 105 patients with chronic hepatitis C treated with interferon who were classified into 28 sustained responders, 34 transient responders, and 43 nonresponders according to alanine aminotransferase normalization. The influence of various patient's characteristics on responses to interferon therapy was investigated by multivariate analysis.
  
  
  RESULTS
  Patients were categorized into 21 patients who exhibited a "smooth liver" on peritoneoscopy and did not demonstrate histologic bridging fibrosis (group I) and 84 patients who exhibited a "granular" or "nodular liver" on peritoneoscopy and/or had histologic bridging fibrosis (group II). Multivariate analysis showed that genotype 2a/2b (p = .0002), low viremia (p = .0048), and early disease stage (group I) (p = .0290) were significant independent factors contributing to sustained response, and that early disease stage (group I) (p = .0010) and genotype 2a/2b (p = .0085) were those contributing to sustained or transient response. Neither peritoneoscopic nor histologic findings alone were a significant factor influencing responses to interferon therapy.
  
  
  CONCLUSIONS
  Disease stage assessed by both peritoneoscopic and histologic findings may serve as a reliable marker for predicting responses to interferon therapy in chronic hepatitis C.
authors.affiliation: First Department of Medicine, Osaka University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ohkawa
authors.forename: N
authors.initials: N
authors.lastname: Hayashi
authors.forename: N
authors.initials: N
authors.lastname: Yuki
authors.forename: A
authors.initials: A
authors.lastname: Kasahara
authors.forename: M
authors.initials: M
authors.lastname: Oshita
authors.forename: K
authors.initials: K
authors.lastname: Mochizuki
authors.forename: K
authors.initials: K
authors.lastname: Katayama
authors.forename: H
authors.initials: H
authors.lastname: Fusamoto
authors.forename: M
authors.initials: M
authors.lastname: Kato
authors.forename: M
authors.initials: M
authors.lastname: Masuzawa
authors.forename: H
authors.initials: H
authors.lastname: Yoshihara
authors.forename: T
authors.initials: T
authors.lastname: Mukuda
authors.forename: T
authors.initials: T
authors.lastname: Kamada
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001707:Biopsy, Needle; D002908:Chronic Disease; D005069:Evaluation Studies as Topic; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use*; D010535:Laparoscopy / Q000379:methods*; D008099:Liver / Q000473:pathology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007372:Interferons